Why the study?
Cardiovascular toxicity is prevalent in cancer survivors, creating a need for succinct guidance on the minimum standard of cardiovascular care required of cancer care providers to improve survivor outcomes.
Provides specific, actionable recommendations for cancer care providers to identify, prevent, and manage cardiovascular toxicity in adults undergoing cancer therapy.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Educating all these healthcare providers [on cardiotoxicity] is necessary. To facilitate communication between specialists, Dr. Dent emphasizes the need for more user-friendly resources. Current guidelines that help doctors evaluate cardiotoxicity risks can be more than one hundred pages long.”
Offers baseline CV care standards for CCPs in cancer survivors; leaves open need for prospective validation before broad adoption.
Purpose Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer. Methods The International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations. Results 5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting systemic CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan. Conclusions CCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally.
No takes yet. Share an insight, caveat, or question.
Dent et al. (2026) conducted a review in Cardiovascular disease in adults with cancer. Cardiovascular risk assessment and management was evaluated. The IC-OS and MASCC clinical practice statement provides five overarching recommendations for cancer care providers to identify, prevent, and manage cardiovascular disease in adults with cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: